BENITIONSClinical Trial Intelligence

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Фаза 2 Завершено NCT00694629

ЗаболеваниеPulmonary Tuberculosis
ФазаФаза 2
СпонсорCenters for Disease Control and Prevention
СтатусЗавершено
Участники334 участн.
Вмешательствоrifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
Дата начала12.2008
Дата завершения06.2013
Публикация результатов23.07.2026

Кратко

This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.

Participants With Negative Sputum Culture at 8 Weeks

8 weeks. · participants

Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol52 participants
lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol62 participants
Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol59 participants
Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol54 participants

Participants Who Discontinued Treatment During Intensive Phase

8 weeks · participants

Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol11 participants
lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol5 participants
Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol5 participants
Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol9 participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.